Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Aug 27;12(1):14640.
doi: 10.1038/s41598-022-18729-0.

Impact of intravenous dexmedetomidine on gastrointestinal function recovery after laparoscopic hysteromyomectomy: a randomized clinical trial

Affiliations
Randomized Controlled Trial

Impact of intravenous dexmedetomidine on gastrointestinal function recovery after laparoscopic hysteromyomectomy: a randomized clinical trial

Yu Wu et al. Sci Rep. .

Abstract

Postoperative intestinal ileus is common after laparoscopic surgery, the incidence of those after hysterectomy was 9.2%. Anesthesia is one of the independent risk factors of postoperative ileus. Dexmedetomidine has been widely used in perioperative anesthesia and previous reports suggested that intraoperative dexmedetomidine may be associated with the improvement of gastrointestinal function recovery after abdominal surgery. We hypothesized that dexmedetomidine could improve gastrointestinal function recovery after laparoscopic hysteromyomectomy. Participants in elective laparoscopic hysteromyomectomy were enrolled with a single dose of 0.5 μg kg-1 dexmedetomidine or the same volume of placebo intravenously administered for 15 min, followed by continuous pumping of 0.2 μg kg-1 h-1 of corresponding drugs until 30 min before the end of surgery. The primary outcome was the time to first flatus. Secondary outcomes were the time to first oral feeding and the first defecation, the occurrence of flatulence, pain score and postoperative nausea and vomiting until 48 h after the surgery. Eventually, 106 participants (54 in dexmedetomidine group and 52 in placebo group) were included for final analysis. The time to first flatus (SD, 25.83 [4.18] vs 27.67 [3.77], P = 0.019), oral feeding time (SD, 27.29 [4.40] vs 28.92 [3.82], P = 0.044), the time to first defecation (SD, 59.82 [10.49] vs 63.89 [7.71], P = 0.025), abdominal distension (n%, 12 (22.2) vs 21 (40.4), P = 0.044), PONV at 24 h (n%, 10 (18.5) vs 19 (36.5), P = 0.037), NRS 6 h (3.15(0.68) vs 3.46 (0.87), P = 0.043) and NRS 12 h (3.43 (0.88) vs 3.85 (0.85), P = 0.014) of dexmedetomidine group were significantly shorter than those of the placebo group. Intraoperative dexmedetomidine reduced the time to first flatus, first oral feeding, and first defecation. These results suggested that this treatment may be a feasible strategy for improving postoperative gastrointestinal function recovery in patients undergoing laparoscopic hysteromyomectomy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
CONSORT flow diagram.
Figure 2
Figure 2
The intraoperative remifentanil consumption of the dexmedetomidine group was significantly lower than those of the control group. Meanwhile, intraoperative sufentanil consumption was similar. The dosages are presented as mean and standard deviation. DEX dexmedetomidine.
Figure 3
Figure 3
The postoperative pain scores of the dexmedetomidine group were significantly lower than those of the control group at 6 h and 12 h after surgery. The scores are presented as mean and standard deviation. DEX dexmedetomidine, NRS numeric rating scale. *P = 0.043, #P = 0.014.

References

    1. van Bree SH, et al. New therapeutic strategies for postoperative ileus. Nat. Rev. Gastroenterol. Hepatol. 2012;9:675–683. doi: 10.1038/nrgastro.2012.134. - DOI - PubMed
    1. Payne SC, Furness JB, Stebbing MJ. Bioelectric neuromodulation for gastrointestinal disorders: Effectiveness and mechanisms. Nat. Rev. Gastroenterol. Hepatol. 2019;16:89–105. doi: 10.1038/s41575-018-0078-6. - DOI - PubMed
    1. Boeckxstaens GE, de Jonge WJ. Neuroimmune mechanisms in postoperative ileus. Gut. 2009;58:1300–1311. doi: 10.1136/gut.2008.169250. - DOI - PubMed
    1. Rami Reddy SR, Cappell MS. A systematic review of the clinical presentation, diagnosis, and treatment of small bowel obstruction. Curr. Gastroenterol. Rep. 2017;19:28. doi: 10.1007/s11894-017-0566-9. - DOI - PubMed
    1. Hoshino N, et al. Daikenchuto for reducing postoperative ileus in patients undergoing elective abdominal surgery. Cochrane Database Syst. Rev. 2018;4:CD012271. doi: 10.1002/14651858.CD012271.pub2. - DOI - PMC - PubMed

Publication types

Substances